Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

Eitemau Tebyg

• Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years
  gan: Schwarz, Tino F, et al.
  Cyhoeddwyd: (2011)
• A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
  gan: Schwarz, Tino F., et al.
  Cyhoeddwyd: (2019)
• Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
  gan: Schwarz, T, et al.
  Cyhoeddwyd: (2015)
• Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
  gan: Romanowski, Barbara, et al.
  Cyhoeddwyd: (2015)
• Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study
  gan: Romanowski, Barbara, et al.
  Cyhoeddwyd: (2014)